29 April 2022 | Comment | Article by Greg Williams
Hugh James advises Development Bank of Wales and BGF on investment into Ceryx Medical Ltd
The Hugh James Corporate and Healthcare team has advised the Development Bank of Wales and the Business Growth Fund (BGF) on their investment into Ceryx Medical Ltd.
Partner, Greg Williams, advised the funders on a £3.8m investment round into the Cardiff-based healthtech start-up which develops bioelectronic technology that mimics nerve centres to control a range of autonomic or rhythmical processes in the human body.
The funding will be used to commercialise Ceryx’s cardiology technology and start the first-in-human clinical study of its cardiac rhythm management device, Cysoni later this year.
Corporate Partner, Greg Williams, who heads the Hugh James Healthcare team, said today:
“It’s been a pleasure to advise Development Bank of Wales, and the Business Growth Fund on this investment into such an exciting project for Ceryx Medical. The transaction demonstrates the funding readily available in the life science sector for innovative, and potentially lifesaving technology.”
You can read more about this deal in this Insider Media article.
Hugh James has a strong track record in advising funders and the life sciences sector. It recently supported Creo Medical Group PLC on its latest expansion.
The information on the Hugh James website is for general information only and reflects the position at the
date of publication. It does not constitute legal advice and should not be treated as such. If you would like
to ensure the commentary reflects current legislation, case law or best practice, please contact the blog author.